Brentuximab vedotin

Full Definition

Brentuximab vedotin is a monoclonal antibody conjugated to a cytotoxic agent that specifically targets CD30, a protein expressed on the surface of certain lymphoma cells. It is primarily used in the treatment of relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma. The drug delivers targeted chemotherapy directly to malignant cells while sparing normal tissues. Common side effects include peripheral neuropathy, which may be dose-limiting in some patients.

Usage

Usage note: Always specify the full drug name in formal documentation; avoid abbreviations in patient records.

In Context

• "The patient received brentuximab vedotin as part of a salvage regimen for relapsed classical Hodgkin lymphoma." — Treatment plan documentation
• "Peripheral neuropathy grade 2 was noted after four cycles of brentuximab vedotin therapy." — Adverse event report